MEDICARE FORM

Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For New Jersey HMO D-SNP:
FAX: 1-833-322-0034
PHONE: 1-844-362-0934

For other lines of business:
Please use other form.

Note: Darzalex Faspro is non-preferred. The preferred products are Bortezomib and Velcade.

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy, Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		DOB:	
Address:		City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	Email:	
Patient Current Weight: ____ lbs or ____ kgs Patient Height: ____ inches or ____ cms			Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured:

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured:

Medicare: ☐ Yes ☐ No If yes, provide ID #:

Medicaid: ☐ Yes ☐ No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:		Last Name:	*(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.		
Address:			City:	State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Oncologist** ☐ **Hematologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other
Name: _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

E. PRODUCT INFORMATION

Request is for: ☐ **Darzalex Faspro (daratumumab and hyaluronidase-fihj)** **Dose:** _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: ☐ _____ **Secondary ICD Code :** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For ALL Requests (clinical documentation required for all requests):

Note: Darzalex Faspro is non-preferred. The preferred products are Bortezomib and Velcade.

☐ Yes ☐ No Has the patient had prior therapy with Darzalex Faspro within the last 365 days?

☐ Yes ☐ No Has the patient had a trial and failure, intolerance, or contraindication to any of the following? (select all that apply)
☐ Velcade ☐ Bortezomib

Please explain if there are any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient's diagnosis? (select all that apply)
☐ Velcade ☐ Bortezomib

_____

_____

Continued on next page

MEDICARE FORM

Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For New Jersey HMO D-SNP:
FAX: 1-833-322-0034
PHONE: 1-844-362-0934

For other lines of business:
Please use other form.

Note: Darzalex Faspro is non-preferred. The preferred products are Bortezomib and Velcade.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

☐ **Light chain amyloidosis**

☐ Yes ☐ No Is the patient newly diagnosed with light chain amyloidosis?
- ☐ Yes ☐ No Is the patient's disease relapsed or refractory?
- ☐ Yes ☐ No Will the requested drug be used in combination with bortezomib, cyclophosphamide and dexamethasone?

☐ **Multiple myeloma**

What is the prescribed regimen?

☐ The requested medication in combination with bortezomib, thalidomide, and dexamethasone
- ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?
- ☐ Yes ☐ No Will the requested medication be used for a maximum of 16 doses?

☐ The requested medication in combination with lenalidomide and dexamethasone
- ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?
- ☐ Yes ☐ No Has the patient received one or more prior therapies?

☐ The requested medication in combination with bortezomib, melphalan, and prednisone
- ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?

☐ The requested medication in combination with bortezomib and dexamethasone
- ☐ Yes ☐ No Has the patient received at least one prior therapy?

☐ The requested medication in combination with carfilzomib and dexamethasone
- ☐ Yes ☐ No Is the patient's disease relapsed or progressive?

☐ The requested medication in combination with pomalidomide and dexamethasone
- ☐ Yes ☐ No Has the patient received at least two prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?

☐ The requested medication as a single agent
- ☐ Yes ☐ No Has the patient received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?
  - ☐ Yes ☐ No Is the patient double refractory to a proteasome inhibitor (PI) and an immunomodulatory agent?

☐ The requested medication in combination with cyclophosphamide, bortezomib, and dexamethasone

☐ The requested medication will be used in combination with bortezomib, lenalidomide and dexamethasone
- ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?

☐ Other

For Continuation Requests (clinical documentation required for all requests)

☐ Yes ☐ No Has the patient experienced disease progression or unacceptable toxicity while on the current regimen?
- Please select: ☐ Disease progression ☐ Unacceptable toxicity

For light chain amyloidosis only:

☐ Yes ☐ No Will the treatment duration exceed 24 months of treatment?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.